Patients must have histologically confirmed malignancy that is metastatic or unresectable and for which standard Food and Drug Administration (FDA)-approved systemic curative or palliative antitumor therapies do not exist or are no longer effective or for which MK- (pembrolizumab) is FDA-approved as standard of care therapy
Patients must have histologically or cytologically confirmed non-Hodgkins lymphoma for which standard therapies do not exist or are no longer effective; to be eligible for this study, lymphoma patients must have no marrow involvement as documented by routine marrow aspiration and biopsy performed within  days of study entry
Participant must have histologically or cytologically confirmed advanced malignancies, except all forms of leukemia and lymphoma, for which standard curative or palliative measures do not exist, are no longer effective, or are not acceptable to the participant
COHORT : ENDOMETRIAL CANCER: Patients must have histologically or cytologically confirmed persistent or recurrent advanced or metastatic invasive endometrial cancer (EC) for which standard curative measures do not exist or are no longer effective
Patients must have histologically confirmed HER-positive breast cancer for which standard curative measures do not exist or are no longer effective; HER testing must have been performed in a laboratory accredited by the College of American Pathologists (CAP) or another accrediting entity
Patients must have histologically confirmed progressive brain metastases from melanoma, or recurrent/progressive malignant glioma (glioblastoma, anaplastic glioma), for which standard curative or palliative measures do not exist or are no longer effective
Standard, curative or palliative measures do not exist or are no longer effective
Malignancy that is incurable and for which standard (FDA approved or established standard clinical practice) curative, or palliative measures do not exist or are no longer effective
Subjects with advanced refractory cancer for which standard curative or palliative\n             measures do not exist or are no longer effective. There is no limitation on the\n             number or types of prior therapy.
Multiple myeloma (MM), limited to those patients for whom standard curative or palliative treatments do not exist or are no longer effective
Non-Hodgkin's lymphoma (NHL), limited to those patients for whom standard curative or palliative treatment do not exist or are no longer effective,
Hodgkin's lymphoma (HL), limited to those patients for whom standard curative or palliative treatment do not exist or are no longer effective
Patients must have a diagnosis and documented disease progression of a solid tumor malignancy, excluding primary brain tumor, for which standard, curative, or life prolonging treatment does not exist or is no longer effective
Patients must have prostate cancer that is advanced or recurrent and for which standard curative or reliable palliative therapies do not exist or are no longer effective
Patients must have a histologically or cytologically confirmed lymphoid malignancy (like Hodgkin lymphoma or one of the mature B- or T-cell non-Hodgkin lymphomas as classified by World Health Organization [WHO]) for which standard curative or palliative measures do not exist or are no longer effective
Diagnosis of systemic anaplastic large-cell lymphoma (sALCL), or HL for which standard, curative, life-prolonging, or palliative treatment does not exist or is no longer effective
Patients are eligible if standard or palliative measures do not exist or are no longer effective; at least  weeks should have elapsed since the last treatment and patients should have recovered from previous significant toxicity (i.e. to grade  or less); alopecia, skin discoloration, nail changes and other cosmetic changes are not considered significant toxicities; there is no limit on the number of prior therapies; patients may have received prior cisplatin or other platinum regimens
Diagnosis of AML, Multiple myeloma, Hodgkin's or Non-Hodgkin's lymphoma for whom standard curative or palliative measures do not exist or are no longer effective
Participants must have disease that is relapsed or refractory and for which standard curative or palliative measures do not exist or are no longer effective
